At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
Degarelixdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Six Month, Multi-centre, Open-labelled, 1:1:1 Randomised, Parallel Group Study Investigating the Efficacy and Safety of Three Dose Regimens of FE 200486 in Prostate Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Degarelix for Prostate Cancer. Completed, enrolled 129 participants across 16 sites.
Detailed Summary
The purpose of this trial was to select a dose of degarelix (FE 200486). Three groups of patients were treated for six months on different doses. The patients had blood samples taken and measured for Testosterone in order to determine the most efficient dose to provide fast and sustained castration. The patients came to the clinic for 16 visits and dependent on the blood sample results they were invited to return for additional blood samples on a two weekly basis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2001
Primary CompletionMay 2002
Study CompletionAug 2002
First PostedJan 2009
TodayJul 2026
First PostedJan 8, 2009
Enrollment StartMar 1, 2001
Primary CompletionMay 1, 2002
Study CompletionAug 1, 2002
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.5 years ago
Interventions
Degarelixdrug
Given as a subcutaneous injection.